Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Tamara Ghanem

- PMLiVE

Indegene acquires DT Associates

Provides end-to-end enterprise solution for customer excellence – from consulting to operations

Building the Lucid Group Brand

Dennis O'Brien, Lucid Group CEO, discusses how they will grow the organisation and develop the Lucid Group brand over the next twelve years.

Lucid Group Communications Limited

- PMLiVE

ALK-Abello debuts its birch pollen allergy therapy in Germany

Key market for the new product

Novartis building

Novartis expands its generics franchise with natalizumab biosimilar

Says affordability is a challenge to access

- PMLiVE

TMC’s full data for inclisiran impresses at ESC

Marketing applications expected before end of year

- PMLiVE

Medimmune-born Viela files $150m IPO, eyes first product launch

Funds will help to push a number of pipeline candidates

- PMLiVE

Ardelyx gets second kidney disease trial win for tenapanor

Drug hit primary and all secondary endpoints

- PMLiVE

AZ unveils phase 3 Brilinta data in CAD and type 2 diabetes

Reduces CV events but falls down on increased bleeding risk

Roche Basel Switzerland

Roche’s flu drug Xofluza scores phase 3 primary endpoint

Demonstrates efficacy as a preventative treatment

armadillo in chains

Should there be a punishment?

I mean for people who use the word innovation willy-nilly.Is it just us here at P&P, or has the word lost its meaning? Dictionaries define it as a new idea...

Page & Page Health

- PMLiVE

Amgen takes aim at Alexion’s patents for Soliris

Follows extension of Soliris patent protection until 2027

- PMLiVE

AZ’s Farxiga heart failure results wow the ESC

Chases after market leader Jardiance

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links